Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 10/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27613286 | 1.00 | BCHE (0.43) | BCHEGNAO1GNAI3GNAI1USP2 | |
| SCHEMBL28296736 | 0.98 | BCHE (0.40) | BCHEGNAO1GNAI3GNAI1USP2 | |
| SCHEMBL1072560 | 0.94 | NR1I2 (0.36) | BCHEGNAO1GNAI3GNAI1USP2 | |
| SCHEMBL27663007 | 0.81 | GNAO1 (0.35) | GNAO1GNAI3GNAI1GBA1S1PR4 | |
| SCHEMBL14437894 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL30306891 | 0.81 | GNAI3 (0.50) | BCHEGNAO1GNAI3GNAI1 | |
| SCHEMBL293862 | 0.79 | GNAO1 (0.39) | GNAO1GNAI3GNAI1GBA1S1PR4 | |
| SCHEMBL10983481 | 0.77 | BCHE (0.56) | BCHESMN1; SMN2POLBGBA1S1PR4 | |
| SCHEMBL8501215 | 0.77 | BCHE (0.56) | BCHESMN1; SMN2POLBGBA1S1PR4 | |
| SCHEMBL16618489 | 0.77 | BCHE (0.56) | BCHESMN1; SMN2POLBGBA1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | BCHE 1964/4885GNAO1 4589/4885GNAI3 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.